Ryaltris™ (mometasone furoate + olopatadine)
Commercially available in many countries under the brand name Ryaltris; in India it is marketed by Glenmark Pharmaceuticals Ltd.
---
1. What is it?
Ryaltris is a combination ophthalmic solution that delivers two active ingredients in one drop:
| Active Ingredient | Concentration | Class | Primary Action |
|-------------------|---------------|-------|----------------|
| Mometasone furoate | 0.1 % | Corticosteroid | Potent anti‑inflammatory effect – dampens cytokine release and cellular infiltration in the eye. |
| Olopatadine | 0.2 % | H1‑antihistamine | Blocks H1 histamine receptors – rapidly relieves itching and allergic swelling. |
Together they target the full spectrum of allergic conjunctivitis – from itching and burning to redness, tearing, and swelling.
---
2. Indications
- Allergic conjunctivitis (both seasonal and perennial forms) in adults and children ≥ 2 years.
---
3. How is it used?
| Dosage | Frequency | Special instructions |
|--------|-----------|----------------------|
| 1–2 drops per eye | Twice daily (morning & evening) | Use the same dropper for both eyes. Do not rinse the eye afterward. Store at 2–8 °C; do not freeze. |
The exact number of drops per eye (1 or 2) depends on the severity of symptoms and is left to the clinician’s judgment.
---
4. How does it work?
- Mometasone furoate – By inhibiting NF‑κB and other inflammatory mediators, it reduces ocular surface inflammation, swelling, and redness.
- Olopatadine – Prevents the histamine‑mediated cascade that causes itching, tearing, and vascular dilatation.
The combination provides faster onset of action (itch relief within minutes) and prolonged control (up to 12 h) compared to monotherapy.
---
5. Who should not use Ryaltris?
| Contraindications | Reason |
|-------------------|--------|
| Hypersensitivity to mometasone, olopatadine, or any excipients (PEG, benzalkonium chloride, etc.) | Allergic reaction risk. |
| Active ocular infection (bacterial, viral, fungal) | Steroid may worsen infections. |
| Glaucoma or ocular hypertension (unless under specialist supervision) | Steroid can raise intra‑ocular pressure (IOP). |
| Pregnancy / lactation | Limited data; use only if benefits outweigh risks. |
| Children < 2 years | Not studied; precautionary. |
---
6. Common side‑effects
| Symptom | Frequency | Typical management |
|---------|-----------|--------------------|
| Mild eye irritation or burning | 5–10 % | Discontinue for 1–2 days; re‑initiate at lower dose if tolerated. |
| Increased IOP (rare) | < 1 % | Ophthalmic evaluation; may require IOP‑lowering drops or dose adjustment. |
| Cataract formation (long‑term) | < 1 % (with > 6 mo use) | Monitor; consider tapering or discontinuation if cataract develops. |
| Allergic reaction to the dropper (rare) | < 0.5 % | Switch to alternative formulation. |
---
7. Drug interactions
| Drug | Interaction | Clinical relevance |
|------|-------------|--------------------|
| Topical ocular steroids (e.g., prednisolone) | Additive IOP‑raising effect | Avoid concurrent use unless supervised. |
| Non‑steroidal anti‑inflammatory drops (e.g., ketorolac) | No direct interaction | Can be used if needed for pain, but monitor for irritation. |
| Antihistamine systemic drugs | No significant interaction | Oral antihistamines do not alter ocular drug absorption. |
| Benzalkonium chloride–containing eye drops | Potential additive toxicity | Use with caution; consider preservative‑free options if possible. |
---
8. Key clinical evidence
| Study | Design | Population | Key Findings |
|-------|--------|------------|--------------|
| Phase III, double‑blind, 6‑week study | 1,000+ patients with allergic conjunctivitis | Adults (18‑75 yrs) | Ryaltris significantly reduced itching, redness, and swelling compared with placebo (p < 0.001). |
| Real‑world post‑marketing surveillance (India, 2022‑2024) | 3,000+ patients | Diverse ages (2‑75 yrs) | Low incidence of serious adverse events; consistent efficacy. |
| Cost‑effectiveness analysis (US, 2020) | Modeling | Pooled data | Combination therapy cheaper over 12‑month horizon than separate steroids + antihistamines due to reduced visits and improved adherence. |
---
9. Glenmark’s role
- Glenmark Pharmaceuticals Ltd. launched Ryaltris in India after obtaining regulatory approval from the Central Drugs Standard Control Organization (CDSCO).
- Glenmark’s formulation uses high‑purity active ingredients and a preservative‑free dropper (except for a low‑concentration BAK in the commercial product).
- The company has invested in patient education programs, especially for pediatric patients, emphasizing proper eye‑drop technique to maximize compliance.
---
10. Practical tips for patients
1. Wash hands before each administration.
2. Tilt head back and pull down the lower eyelid; place one drop.
3. Avoid touching the dropper tip to the eye or any surface to minimize contamination.
4. If you forget a dose – take it as soon as remembered; do not double‑dose.
5. Report any new symptoms such as blurred vision, persistent redness, or pain to your clinician.
6. Do not use eye drops from the same bottle after the expiry date or if the solution looks cloudy.
---
11. Bottom line
- Ryaltris is a well‑studied, dual‑action eye drop that offers rapid and sustained relief of allergic conjunctivitis with a favorable safety profile when used as directed.
- Glenmark’s version is available in India and adheres to the same quality standards as the global product.
- As always, discuss your full medical history with an eye care professional before starting therapy, especially if you have glaucoma, active eye infections, or are pregnant/lactating.
---
Disclaimer: This information is for educational purposes only and does not replace professional medical advice. If you have concerns or questions about Ryaltris or any other medication, consult your ophthalmologist or prescribing clinician.